T2 Biosystems Inc (TTOO) Receives $6.83 Average PT from Analysts

T2 Biosystems Inc (NASDAQ:TTOO) has been given an average rating of “Hold” by the eight ratings firms that are currently covering the company, MarketBeat reports. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. The average 1-year price target among brokers that have covered the stock in the last year is $6.83.

Several analysts recently issued reports on TTOO shares. ValuEngine raised T2 Biosystems from a “strong sell” rating to a “sell” rating in a report on Wednesday, September 13th. HC Wainwright reissued a “buy” rating and issued a $8.00 price target on shares of T2 Biosystems in a report on Friday, November 3rd. Zacks Investment Research raised T2 Biosystems from a “hold” rating to a “buy” rating and set a $4.75 price target on the stock in a report on Wednesday, November 8th. Finally, Canaccord Genuity reissued a “buy” rating and issued a $6.00 price target on shares of T2 Biosystems in a report on Monday, October 30th.

A number of institutional investors and hedge funds have recently bought and sold shares of TTOO. Senvest Management LLC increased its position in T2 Biosystems by 15.2% in the 2nd quarter. Senvest Management LLC now owns 2,837,946 shares of the medical equipment provider’s stock valued at $9,110,000 after acquiring an additional 373,876 shares during the period. Goldman Sachs Group Inc. increased its position in T2 Biosystems by 0.4% in the 2nd quarter. Goldman Sachs Group Inc. now owns 4,270,632 shares of the medical equipment provider’s stock valued at $13,709,000 after acquiring an additional 18,000 shares during the period. Lagoda Investment Management L.P. increased its position in T2 Biosystems by 15.4% in the 2nd quarter. Lagoda Investment Management L.P. now owns 1,975,921 shares of the medical equipment provider’s stock valued at $6,343,000 after acquiring an additional 264,337 shares during the period. Susquehanna International Group LLP increased its position in T2 Biosystems by 931.3% in the 2nd quarter. Susquehanna International Group LLP now owns 85,620 shares of the medical equipment provider’s stock valued at $275,000 after acquiring an additional 95,920 shares during the period. Finally, Essex Investment Management Co. LLC increased its position in T2 Biosystems by 239.2% in the 3rd quarter. Essex Investment Management Co. LLC now owns 706,194 shares of the medical equipment provider’s stock valued at $2,966,000 after acquiring an additional 498,004 shares during the period. Hedge funds and other institutional investors own 59.73% of the company’s stock.

T2 Biosystems (NASDAQ TTOO) traded down $0.14 during trading hours on Monday, reaching $5.42. The company’s stock had a trading volume of 384,406 shares, compared to its average volume of 422,451. The company has a current ratio of 5.40, a quick ratio of 5.28 and a debt-to-equity ratio of 2.25. T2 Biosystems has a 52 week low of $2.50 and a 52 week high of $6.99. The company has a market cap of $197.04, a P/E ratio of -2.84 and a beta of 1.48.

T2 Biosystems (NASDAQ:TTOO) last released its earnings results on Thursday, November 2nd. The medical equipment provider reported ($0.45) EPS for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.04. T2 Biosystems had a negative return on equity of 244.82% and a negative net margin of 1,497.70%. The company had revenue of $1.11 million for the quarter, compared to the consensus estimate of $1.10 million. The company’s quarterly revenue was up 2.8% on a year-over-year basis. analysts anticipate that T2 Biosystems will post -1.85 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This article was first reported by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this article on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark law. The legal version of this article can be viewed at https://stocknewstimes.com/2018/01/12/t2-biosystems-inc-ttoo-receives-6-83-average-pt-from-analysts.html.

About T2 Biosystems

T2 Biosystems, Inc is an in vitro diagnostics company engaged in developing a technology platform offering an alternative to diagnostic methodologies. The Company’s T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL).

Analyst Recommendations for T2 Biosystems (NASDAQ:TTOO)

Receive News & Ratings for T2 Biosystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for T2 Biosystems and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply